PCSK9-9 inhibition in cardiology

Abstract

Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK-9 inhibitors) can further lower LDL-C by 60% in statin-treated patients.

Keywords

• cholesterol
• drug therapy
• LDL cholesterol metabolism